GlaxoSmithKline backs 2019 adjusted EPS view down 5%-9% CER

The company said: “In 2019, we continue to expect Adjusted EPS to decline in the range of -5% to -9% at CER. This guidance reflects the recent approval of a substitutable generic competitor to Advair in the US and the expected impact of the Tesaro acquisition and assumes that the proposed Consumer Healthcare nutrition disposal closesby the end of 2019 and the proposed Consumer Healthcare Joint Venture with Pfizer closes during H2 2019. GSK expects to maintain the dividend for 2019 at the current level of 80p per share.”

https://thefly.com/landingPageNews.php?id=2900845